<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02300701</url>
  </required_header>
  <id_info>
    <org_study_id>ADAPT</org_study_id>
    <nct_id>NCT02300701</nct_id>
  </id_info>
  <brief_title>Role of Anti-IgE in Severe Childhood Eczema</brief_title>
  <acronym>ADAPT</acronym>
  <official_title>The Role of Anti-IgE (Omalizumab) in the Management of Severe Recalcitrant Paediatric Atopic Eczema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guy's and St Thomas' NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute for Health Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Guy's and St Thomas' NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of anti-IgE (Omalizumab/Xolair) in children with severe eczema.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To address the value of anti-IgE in children with severe eczema.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in atopic eczema</measure>
    <time_frame>24 weeks after treatment commences</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Atopic Eczema</condition>
  <condition>Atopic Dermatitis</condition>
  <condition>Child</condition>
  <arm_group>
    <arm_group_label>Xolair/Omalizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xolair</intervention_name>
    <description>According to manufacturer's instructions</description>
    <arm_group_label>Xolair/Omalizumab</arm_group_label>
    <other_name>Omalizumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Children between the ages of 4-19 years

          2. Severe eczema

          3. Raised SpIgE or SPT to at least 1 food allergen or 1 aeroallergen AND/OR

          4. Clinical impression that allergic exposures cause worsening eczema.

          5. Total IgE level &gt;300 kU/l

          6. Clinically proven IgE-mediated allergic disease.

          7. Written informed consent to participate.

        Exclusion criteria:

          1. Inability to comply with 2-4 weekly injections and clinic visits

          2. Evidence of underlying immune compromise, autoimmune disease, immune complex mediated
             conditions.

          3. Uncontrolled infection or unstable eczema.

          4. Malignancy or a history of malignancy.

          5. Pre-existing hepatic or renal impairment

          6. Known cardiovascular or ischaemic cerebrovascular abnormality.

          7. Other serious or uncontrolled systemic disease.

          8. Pregnancy or lactation.

          9. Known history of hypersensitivity or anaphylaxis to anti-IgE injections or its
             constituents.

         10. Insufficient understanding of the trial assessments.

         11. Participation in a CTIMP in the previous 60 days or (if known) 4 half-lives of the
             relevant medication, whichever is the greater.

         12. Investigator feels that there is a good clinical reason why the child would be
             unsuitable.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>19 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>S Chan, MBBS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guy's and St Thomas' Hospitals NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Guy's and St Thomas' NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2014</study_first_submitted>
  <study_first_submitted_qc>November 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2014</study_first_posted>
  <last_update_submitted>February 14, 2018</last_update_submitted>
  <last_update_submitted_qc>February 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omalizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

